Breaking! Meta-Analysis Of 11 Randomized Clinical Trials Of Chloroquine and Hydroxychloroquine Shows That It Is Totally Ineffective To Treat COVID-19 And Actually Causes Adverse Events.
COVID-19 Drug Research
: A new meta-analysis collaborative study by medical researchers from the University of San Diego and Yantai Yuhuangding Hospital in Shandong and also Shengjing Hospital in Shenyang, both in China, has confirmed that both Chloroquine and Hydroxychloroquine are both not effective for treating the COVID-19 disease and in fact caused a variety of adverse events in most patients. https://www.medrxiv.org/content/10.1101/2020.04.13.20064295v1.full.pdf+html
The medical researchers searched PubMed, EMBASE, Cochrane Central, Web of Science, Clinical Trials Registries, CNKI, Wanfang Data, CQVIP, and Preprint Servers through April 4, 2020, for randomized controlled trials (RCTs) that examined the efficacy and safety of CQ and HCQ against various viral infections including COVID-19.
They then meta-analyzed pooled data on the overall efficacy, the relative risks over the placebo, and the prevalence of adverse events. Trial sequential analysis (TSA) was also performed to evaluate the random errors in the meta-analysis.
Also potential moderators of drug placebo efficacy differences were analyzed by meta-regression.
The analysis included 11 Randomized Clinical Trials with 2613 adult patients.
The study results were as such: Both the plasma viral load (standard mean difference: 0.29, 95% CI: -1.19 - 1.76, P = 0.70) and the improvement of clinical symptoms (odds ratio: 2.36, 95% CI: 0.81 - 6.92, P = 0.11) were not different between the intervention and placebo arm. There was significant heterogeneity for the efficacy assessment, which was primarily explained by the mean patients’ age and the sample size. Compared to the placebo, CQ and HCQ had increased risk of mild adverse events (risk ratio: 1.51, 95% CI: 1.35 - 1.70, P < 0.05, TSA adjusted 95% CI: 1.31 - 2.19), which were statistically significant in nervous, integumentary, and gastrointestinal systems. The most common adverse events were observed in the nervous system, with the pooled prevalence of 31.4 % (95% CI: 10.5% - 56.7%).
Cardiotoxicity was also a major concern associated with the usage of chloroquine and hydroxycloroquine.
Many medical experts and healthcare professionals are against the use of these drugs now as they is lack of any efficacy in using them to treat COVID-19 coupled with the dangerous side effects.
In fact certain legal and medical groups are now advocating that legal action should be undertaken again health authorities, governments and also doctors or hospitals are advocating the use or are still using Chloroquine or Hydroxychloroquine in in their treatment protocols to treat COVID-19. Patients are also cautioned to use their rights to reject any medications that they are not comfortable with.
Chloroquine and hydroxychloroquine gained attention as a possible drug to treat COVID-19 after a rogue French doctor had published manipulated results from a clinical trial that was ‘faked’ from the start. https://web.archive.org/web/20200409145548/https://www.isac.world/news-and-publications/official-isac-statemen
However a lot of gullible people started believing in the treatment protocol and are instead indirectly ‘killing’ COVID-19 patients at the moment with its usage.
THE US FDA which advocates the use of the drugs have now joined the ranks of the WHO and US CDC along with certain Chinese governmental agencies as being the biggest sources of fake news, misinformation and fraud with regards to the COVID-19 disease and crisis.
For more on COVID-19 Drug Research
, keep on logging to Thailand Medical News
We desperately need your kind help! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. We are also trying to raise funds to help poor undocumented refugees who have no access to public healthcare during the COVID-19 crisis. Donations are accepted via paypal
Read also: https://edition.cnn.com/2020/04/08/health/cdc-coronavirus-hydroxychloroquine/index.html